Comments of the Healthcare Supply Chain Association (HSCA) on USTR Request for Comments on the Proposed Modification of Action Pursuant to Section 301
On behalf of the Healthcare Supply Chain Association (HSCA), we appreciate the opportunity to provide comments to the U.S. Trade Representative (USTR) on the proposed modification of action regarding Chinese exports under Section 301.
Click here for the full comments.
Lear MoreHSCA Applauds FDA for Releasing New Data to Enable Generic Competition
Washington, DC (June 19, 2019) – Healthcare Supply Chain Association (HSCA) President and CEO Khatereh Calleja today released the following statement applauding the U.S. Food and Drug Administration (FDA) for releasing new data to help generic drug competitors:
Click here for the full statement.
Lear MoreNew Analysis of U.S. Health Data Finds Healthcare Group Purchasing Organizations Save Healthcare System, Medicare and Medicaid, and Taxpayers Up to $34.1 Billion Annually
Analysis of CMS expenditure data finds that GPOs will reduce healthcare spending by $456.6 billion over the next ten years
Washington, DC (May 15, 2019) – The Healthcare Supply Chain Association (HSCA), which represents the nation’s leading healthcare group purchasing organizations (GPOs), today announced a new analysis of data from the Centers for Medicare and Medicaid Services (CMS) found that GPOs save the healthcare industry up to $34.1 billion annually and will reduce healthcare spending by up to $456.6 billion over the next ten years. The report, conducted by healthcare economists at Dobson DaVanzo & Associates, found that GPOs reduce supply-related purchasing costs to nursing homes and hospitals by 13.1 percent compared to providers who do not use GPO services.
Click here to read the full release.
Lear MoreHSCA Applauds House Judiciary Committee for Advancing the CREATES Act
Washington, DC (April 30, 2019) – Healthcare Supply Chain Association (HSCA) President and CEO
Khatereh Calleja today released the following statement applauding the House Judiciary Committee
members for voting to advance the CREATES Act (H.R. 965):
“The Healthcare Supply Chain Association (HSCA) and its member group purchasing organizations
(GPOs) applaud Chairman Nadler, Ranking Member Collins, and the members of the House Judiciary
Committee for helping to increase competition in the generic drug marketplace by voting to advance the
CREATES Act. Americans rely on generic drugs to reduce costs and increase access to necessary
medication, and price spikes for commonly used drugs jeopardize patient access to care. HSCA supports
policy solutions like the CREATES Act that lower drug prices, encourage competition and innovation in
the marketplace, and end anti-competitive abuses utilized by some brand-name manufacturers. We
urge the House to quickly pass the CREATES Act to protect patient access to essential medications.”
Read the full statement here.
Lear MoreHSCA Names Leading National Healthcare Expert Khatereh Calleja as President & CEO
Washington, DC (April 2, 2019) – The Healthcare Supply Chain Association (HSCA) Board of Directors is
pleased to announce that it has named leading national healthcare expert Khatereh Calleja as President
and CEO of the Healthcare Supply Chain Association, effective April 29, 2019. Calleja joins HSCA from
AdvaMed, the world’s largest association representing manufacturers of medical devices, diagnostic
products, and medical information systems, where she served as Senior Vice President of Technology
and Regulatory Affairs.
Click here for the full release.
Lear MoreHSCA E&C Letter on Improving Competition in the Generic Marketplace
Dear Chairman Pallone and Ranking Member Walden,
I am writing to you on behalf of the Healthcare Supply Chain Association (HSCA) to thank you for your continued leadership on the important issue of drug pricing and the pressing need to stop anti-competitive abuses that keep drug prices high. HSCA shares your belief that a competitive marketplace will lower the price of generic drugs and help ensure that price spikes for critical generic drugs do not jeopardize patient access to care.
Click here to read the full letter.
Lear More